Stocktoria
LIFECORE BIOMEDICAL, INC. \DE\ LFCR
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1996-02-15
LIFECORE BIOMEDICAL, INC. \DE\ financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $128.9M | $128.3M | $103.3M | $111.3M | $100.9M | $160.1M | $557.6M | $524.2M | $532.3M | $541.1M |
| Gross profit | $40.3M | $41.9M | $28.0M | $39.1M | $38.9M | $39.4M | $81.0M | $78.3M | $79.2M | $66.8M |
| R&D expense | $8.3M | $8.6M | $8.7M | $7.8M | $6.7M | $7.6M | $11.5M | $12.8M | $9.5M | $7.2M |
| SG&A expense | $44.0M | $40.5M | $39.0M | $34.7M | $27.7M | $40.7M | $62.1M | $52.0M | $52.5M | $46.2M |
| Operating income | -$17.2M | -$8.8M | -$21.8M | -$11.8M | -$8.8M | -$25.9M | $5.5M | $13.6M | $14.7M | -$20.6M |
| Interest expense | — | — | $17.6M | $15.6M | $8.9M | $4.6M | — | — | — | $2.0M |
| Income tax | $43,000 | $183,000 | $308,000 | -$5.2M | -$6.3M | -$8.8M | $1.5M | -$9.4M | $4.0M | -$7.7M |
| Net income | -$38.7M | $12.0M | -$99.6M | -$116.7M | -$32.3M | -$38.2M | $411,000 | $24.8M | $10.6M | -$11.6M |
| EPS (diluted) | $-1.27 | $0.33 | $-3.32 | $-3.97 | $-1.10 | $-1.31 | $0.01 | $0.89 | $0.38 | $-0.43 |
| Operating cash flow | -$206,000 | $257,000 | -$17.4M | -$22.6M | $16.5M | -$17.0M | $16.0M | $19.8M | $29.8M | $21.9M |
| Free cash flow | -$13.6M | -$18.1M | — | -$48.8M | -$2.8M | -$29.3M | -$28.7M | -$13.8M | $6.8M | -$17.8M |
| Cash & equivalents | $8.3M | $8.5M | $19.1M | $991,000 | $763,000 | $360,000 | $1.1M | $2.9M | $6.0M | $10.0M |
| Inventory | $32.3M | $40.0M | $40.8M | $36.0M | $33.9M | $66.3M | $54.1M | $31.8M | $23.6M | $25.5M |
| Total assets | $239.3M | $254.0M | $253.5M | $274.7M | $501.9M | $293.5M | $519.1M | $404.7M | $358.6M | $342.7M |
| Total liabilities | $191.9M | $200.1M | $218.5M | $186.9M | $299.9M | $310.3M | $248.9M | $152.1M | $130.5M | $130.3M |
| Shareholders' equity | $1.3M | $11.3M | -$4.2M | $87.8M | $201.9M | $229.8M | $270.1M | $252.6M | $228.2M | $212.3M |
Growth · year-over-year · Revenue CAGR -14.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +0.5% | +24.2% | -7.2% | +10.3% | -37.0% | -71.3% | +6.4% | -1.5% | -1.6% | +0.3% |
| Net income growth | -422.3% | — | — | — | — | -9392.2% | -98.3% | +134.5% | — | -185.9% |
| EPS growth | -484.8% | — | — | — | — | -13200.0% | -98.9% | +134.2% | — | -186.0% |
| Free cash flow growth | — | — | — | — | — | — | — | -302.1% | — | -295.0% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-05-25. Facts plus Stocktoria's own computed scores — not investment advice.